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What’s Next at AJP?
Within the field of Pathology lies a history of great physi-
cians and experimentalists who have broadened our un-
derstanding of human disease. Today’s pathologists not
only describe disease manifestations, but they also ex-
amine the molecular mechanisms of disease initiation
and progression, discover new paradigms of cellular in-
teractions, and devise novel therapeutics based on such
discoveries. It is this breadth of scientific knowledge that
The American Journal of Pathology will continue to publish
during my tenure as Editor-in-Chief.
I am deeply honored to follow in the footsteps of the
many well-known pathologists who have served as Edi-
tors-in-Chief of the AJP in recent decades, such as Vin-
cent T. Marchesi, Nelson Fausto, James L. Madara, and
Jay M. McDonald. I endeavor to build on their past suc-
cesses while still striving for future growth by increasing
the readership, visibility, and impact of the Journal. As a
firm believer that “actions speak louder than words,” I am
providing below a list of my action items:
1) Broaden the Scope of the Journal. In the front of this
issue you will find the Journal’s newly revised scope,
emphasizing “basic and translational knowledge of the
pathogenesis, classification, diagnosis, and mechanisms
of disease.” To implement this, I encourage submissions
that employ proteomics, gene profiling, and tissue mi-
croarrays to elucidate disease pathogenesis, as the dis-
covery of novel biomarkers is critical to our understand-
ing of human disease. In addition, studies of stem cell
biology and regenerative medicine will be supported as
they represent the future of modern medicine. Finally,
studies reporting clinical and translational medicine as
well as new animal models of disease will also be a high
priority.
2) Increase Associate Editors and Editorial Board Mem-
bers. By expanding the number of Associate Editors and
Editorial Board Members, and thus the Journal’s exper-
tise, we hope to attract a wider readership and authorship
while at the same time cutting down on the workload of
individual Editors and reviewers. This should assist with
the broadened scope and result in a shorter peer review
process.
3) Emphasize Reviews, Mini-Reviews, and Biological
Perspectives. To increase the number of reviews that
appear in every issue, I have recruited a large team of
highly respected Reviews Editors who will actively solicit
Reviews, Mini-Reviews, and Biological Perspectives from
subject-matter experts. We will continue to solicit Com-
mentaries and Editorials, and proposals for uninvited Re-
views should still be submitted for Editorial assessment.
4) Bring Back Short Communications. I enjoy reading
brief reports since such papers are on the cutting edge of
science, often representing the start of a new field. Short
Communications, which are returning to the AJP, should
report timely, significant findings in a concise but defini-
tive manner. We will aim to shorten the review time of
such manuscripts, with the goal of expediting their
publication.
Detailed information regarding all of these changes
can be found in this issue’s Editorial Board page (revised
scope and new Editors) or in the updated Instructions to
Authors (new manuscript types, also online at http://ajp.
amjpathol.org/misc/ifora.shtml).
Finally, although I am not a board-certified pathologist,
I feel like a pathologist at heart. My research interests in
human cellular and molecular pathology range from heart
disease and diabetes, to muscular dystrophy, cancer,
and aging. I have the highest respect for the study of
Pathology and for its premier journal, The American Jour-
nal of Pathology. I have been a member of ASIP since
2002, have published numerous papers in AJP, and have
been on the AJP Editorial Board since 2004.
Now, as the Editor-in-Chief of the AJP, I will continue
the tradition of excellence associated with the Journal
and the field of Pathology. And I encourage the input of
the Journal’s readers and authors as I embrace this ex-
citing challenge.
Michael P. Lisanti, M.D., Ph.D.
Editor-in-Chief
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